These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
117 related articles for article (PubMed ID: 11886762)
41. Mammographic density changes in women on hormone replacement therapy. Dalessandri KM Climacteric; 2002 Mar; 5(1):92-3. PubMed ID: 11974566 [No Abstract] [Full Text] [Related]
42. Less mammographic density after nasal versus oral administration of postmenopausal hormone therapy. van Dijck JA; Otten JD; Karssemeijer N; Kenemans P; Verbeek AL; van der Mooren MJ Climacteric; 2011 Dec; 14(6):683-8. PubMed ID: 21942620 [TBL] [Abstract][Full Text] [Related]
43. Insulin-like growth factor and mammographic density in postmenopausal Norwegian women. Bremnes Y; Ursin G; Bjurstam N; Rinaldi S; Kaaks R; Gram IT Cancer Epidemiol Biomarkers Prev; 2007 Jan; 16(1):57-62. PubMed ID: 17220332 [TBL] [Abstract][Full Text] [Related]
44. Pain and increased mammographic density in women receiving hormone replacement therapy: a prospective study. McNicholas MM; Heneghan JP; Milner MH; Tunney T; Hourihane JB; MacErlaine DP AJR Am J Roentgenol; 1994 Aug; 163(2):311-5. PubMed ID: 8037021 [TBL] [Abstract][Full Text] [Related]
45. The DAMA trial: a diet and physical activity intervention trial to reduce mammographic breast density in postmenopausal women in Tuscany, Italy. Study protocol and baseline characteristics. Masala G; Assedi M; Caini S; Ermini I; Occhini D; Castaldo M; Bendinelli B; Zagni D; Tanzini D; Saieva C; Ambrogetti D; Palli D Tumori; 2014; 100(4):377-85. PubMed ID: 25296586 [TBL] [Abstract][Full Text] [Related]
46. Endogenous hormone levels, mammographic density, and subsequent risk of breast cancer in postmenopausal women. Tamimi RM; Byrne C; Colditz GA; Hankinson SE J Natl Cancer Inst; 2007 Aug; 99(15):1178-87. PubMed ID: 17652278 [TBL] [Abstract][Full Text] [Related]
47. Longitudinal measurement of clinical mammographic breast density to improve estimation of breast cancer risk. Kerlikowske K; Ichikawa L; Miglioretti DL; Buist DS; Vacek PM; Smith-Bindman R; Yankaskas B; Carney PA; Ballard-Barbash R; J Natl Cancer Inst; 2007 Mar; 99(5):386-95. PubMed ID: 17341730 [TBL] [Abstract][Full Text] [Related]
49. Effects of tibolone and continuous combined hormone replacement therapy on mammographic breast density. Lundström E; Christow A; Kersemaekers W; Svane G; Azavedo E; Söderqvist G; Mol-Arts M; Barkfeldt J; von Schoultz B Am J Obstet Gynecol; 2002 Apr; 186(4):717-22. PubMed ID: 11967497 [TBL] [Abstract][Full Text] [Related]
50. Effect of ultra-low-dose transdermal estradiol on breast density in postmenopausal women. Grady D; Vittinghoff E; Lin F; Hanes V; Ensrud K; Habel LA; Wallace R; Macer J; Cummings SR; Shepherd J Menopause; 2007; 14(3 Pt 1):391-6. PubMed ID: 17224859 [TBL] [Abstract][Full Text] [Related]
51. Perspectives on the Women's Health Initiative trial of hormone replacement therapy. Grimes DA; Lobo RA Obstet Gynecol; 2002 Dec; 100(6):1344-53. PubMed ID: 12468183 [TBL] [Abstract][Full Text] [Related]
52. Use of hormone therapy and isoflavones and mammographic density in Spain. Isidoro B; Lope V; Whelan D; Pedraz C; Sánchez-Contador C; Santamariña C; Moreo P; Vidal C; Salas-Trejo D; Ederra M; Aragonés N; Pérez-Gómez B; Pollán M Menopause; 2016 May; 23(5):556-64. PubMed ID: 26731688 [TBL] [Abstract][Full Text] [Related]
53. Breast cancer: when and how often to get screened. How do you make sense of conflicting mammography guidelines? Harv Womens Health Watch; 2013 Oct; 21(2):3. PubMed ID: 24432454 [No Abstract] [Full Text] [Related]
54. Hormone replacement therapy and false positive recall in the Million Women Study: patterns of use, hormonal constituents and consistency of effect. Banks E; Reeves G; Beral V; Bull D; Crossley B; Simmonds M; Hilton E; Bailey S; Barrett N; Briers P; English R; Jackson A; Kutt E; Lavelle J; Rockall L; Wallis MG; Wilson M; Patnick J Breast Cancer Res; 2006; 8(1):R8. PubMed ID: 16417651 [TBL] [Abstract][Full Text] [Related]
55. [A mammographic evaluation of the morphostructural variations of the breast during hormone-replacement therapy in the postmenopause]. Porfiri LM; Costanza L; De Felice C; Perrone G; David V; Zichella L Radiol Med; 1998 Jun; 95(6):573-6. PubMed ID: 9717537 [TBL] [Abstract][Full Text] [Related]
56. Invited Commentary: Hormone therapy risks and benefits--The Women's Health Initiative findings and the postmenopausal estrogen timing hypothesis. Banks E; Canfell K Am J Epidemiol; 2009 Jul; 170(1):24-8. PubMed ID: 19468078 [TBL] [Abstract][Full Text] [Related]
57. Histologic changes in the breast with menopausal hormone therapy use: correlation with breast density, estrogen receptor, progesterone receptor, and proliferation indices. Harvey JA; Santen RJ; Petroni GR; Bovbjerg VE; Smolkin ME; Sheriff FS; Russo J Menopause; 2008; 15(1):67-73. PubMed ID: 17558338 [TBL] [Abstract][Full Text] [Related]
58. Postmenopausal hormone therapy and mammographic breast density. Marchesoni D; Driul L; Ianni A; Fabiani G; Della Martina M; Zuiani C; Bazzocchi M Maturitas; 2006 Jan; 53(1):59-64. PubMed ID: 15939560 [TBL] [Abstract][Full Text] [Related]
59. The Million Women Study and breast cancer. Speroff L Maturitas; 2003 Sep; 46(1):1-6. PubMed ID: 12963165 [No Abstract] [Full Text] [Related]
60. Polymorphisms in genes involved in estrogen and progesterone metabolism and mammographic density changes in women randomized to postmenopausal hormone therapy: results from a pilot study. Lord SJ; Mack WJ; Van Den Berg D; Pike MC; Ingles SA; Haiman CA; Wang W; Parisky YR; Hodis HN; Ursin G Breast Cancer Res; 2005; 7(3):R336-44. PubMed ID: 15987428 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]